Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001245-24
    Sponsor's Protocol Code Number:GS-US-337-1118
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-07-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-001245-24
    A.3Full title of the trial
    An open-Label, multicenter study to evaluate the efficacy and safety of sofosbuvir/ledipasvir fixed-dose combination ±
    ribavirin for 12 or 24 weeks in chronic genotype 1 HCV infected subjects who participated in a prior gilead-sponsored HCV treatment study
    Estudio multicéntrico, abierto para evaluar la eficacia y seguridad de la combinación a dosis fija de sofosbuvir/ledipasvir con o sin ribavirina durante 12 ó 24 semanas en pacientes con infección crónica por VHC genotipo 1 que participaron en un estudio previo de tratamiento del VHC patrocinado por Gilead
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An international study to assess the safety and efficacy of a combination of new investigational drugs in patients with chronic hepatitis C virus infection who have previously failed treatment in a clinical study run by Gilead.
    Estudio internacional para evaluar la seguridad y eficacia de una combinación de nuevos medicamentos en investigación en pacientes con infección crónica por virus de la hepatitis C cuyo tratamiento previo en un estudio patrocinado por Gilead haya fracasado.
    A.4.1Sponsor's protocol code numberGS-US-337-1118
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGilead Sciences, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGilead Sciences Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGilead Sciences Inc.
    B.5.2Functional name of contact pointMedical Monitor
    B.5.3 Address:
    B.5.3.1Street Address333 Lakeside Drive
    B.5.3.2Town/ cityFoster City, CA
    B.5.3.3Post code94404
    B.5.3.4CountryUnited States
    B.5.4Telephone number+16505743000
    B.5.5Fax number+16505789264
    B.5.6E-mailclinical.trials@gilead.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSofosbuvir/Ledipasvir FDC
    D.3.2Product code GS-7977/GS-5885 FDC
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSofosbuvir
    D.3.9.1CAS number 1190307-88-0
    D.3.9.2Current sponsor codeGS-7977
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number400
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGS-5885
    D.3.9.2Current sponsor codeGS-5885
    D.3.9.3Other descriptive nameGS-5885
    D.3.9.4EV Substance CodeSUB32080
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number90
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ribasphere Tablets
    D.2.1.1.2Name of the Marketing Authorisation holderThree Rivers Pharmaceuticals, LLC
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRibasphere
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRibavirin
    D.3.9.1CAS number 36791-04-5
    D.3.9.4EV Substance CodeSUB10297MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Genotype 1 Hepatitis C Virus Infection
    Infección crónica por el virus de la hepatitis C genotipo 1
    E.1.1.1Medical condition in easily understood language
    Hepatitis C Virus Infection
    Infección por el virus de la hepatitis C
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level LLT
    E.1.2Classification code 10019751
    E.1.2Term Hepatitis C virus
    E.1.2System Organ Class 100000004848
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objectives of this study are:
    - To determine the efficacy of sofosbuvir/ledipasvir fixed-dose combination (SOF/LDV FDC) ± ribavirin (RBV) as measured by the proportion of subjects with sustained viral response at 12 weeks after discontinuation of therapy (SVR12).
    - To evaluate the safety and tolerability of SOF/LDV FDC ± RBV as assessed by review of the accumulated safety data.
    Los objetivos principales de este estudio son los siguientes:
    - Determinar la eficacia de CDF SOF/LDV con o sin RBV, conforme a la proporción de pacientes con una respuesta virológica sostenida en la semana 12 tras la interrupción del tratamiento (RVS12).
    - Evaluar la seguridad y tolerabilidad de CDF SOF/LDV con o sin RBV, determinadas mediante la revisión de los datos de seguridad acumulados.
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are:
    - To determine the proportion of subjects who attain SVR at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)
    - To evaluate the kinetics of plasma HCV RNA during and after treatment discontinuation
    - To evaluate the emergence of viral resistance to SOF and LDV during and after treatment discontinuation
    Los objetivos secundarios de este estudio son los siguientes:
    - Determinar la proporción de pacientes que alcanzan una RVS a las 4 y 24 semanas tras la interrupción del tratamiento (RVS4 y RVS24).
    - Evaluar la cinética del ARN del VHC en plasma durante el tratamiento y tras la interrupción de este.
    - Evaluar la aparición de resistencia vírica a SOF y LDV durante el tratamiento y tras la interrupción de este.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Registry Studies
    Sequence Registry Study
    Subjects who do not achieve SVR24 will be eligible for enrollment in the Sequence Registry Study. The purpose of the Sequence Registry Study will be to monitor the persistence of resistant mutations for up to 3 years. The Sequence Registry Study is described in a separate protocol (GS-US-248-0123).

    SVR Registry Study
    Subjects who achieve SVR24 will be eligible for enrollment in the SVR Registry Study. The purpose of the SVR Registry Study will be to evaluate durability of SVR for up to 3 years post-treatment. The SVR Registry Study is described in a separate protocol (GS-US-248- 0122).

    Cirrhosis SVR Registry Study
    Cirrhotic subjects who achieve SVR24 will be eligible for enrollment in the Cirrhosis SVR Registry Study. The purpose of the Cirrhosis SVR Registry Study will be to evaluate durability of SVR and the progression or regression of liver disease for up to 5 years Post-Treatment. The Cirrhosis SVR Registry Study is described in a separate protocol (GS-US-337-1431).
    Estudios de registro
    Estudio de registro de secuencia
    Los pacientes que no alcancen la RVS24 serán aptos para participar en el estudio de registro de secuencia. El objetivo del estudio de registro de secuencia será monitorizar la persistencia de mutaciones que confieren resistencia durante un máximo de 3 años. Este estudio se describe en un protocolo aparte (GS-US-248 0123).

    Estudio de registro de RVS
    Todos los pacientes que alcancen la RVS24 serán aptos para participar en el estudio de registro de RVS. El objetivo del estudio de registro de RVS será evaluar la durabilidad de la RVS durante un máximo de 3 años postratamiento. Este estudio se describe en un protocolo aparte (GS-US-248-0122).

    Estudio de registro de RVS y cirrosis
    Los pacientes con cirrosis que alcancen una RVS24 serán aptos para participar en el estudio de registro de RVS y cirrosis. El objetivo del estudio de registro de RVS y cirrosis será evaluar la durabilidad de la RVS y la progresión o regresión de la hepatopatía durante un máximo de 5 años postratamiento. Este estudio se describe en un protocolo aparte (GS-US-337-1431).
    E.3Principal inclusion criteria
    Subjects must meet all of the following inclusion criteria to be eligible for participation in this
    study.
    1) Willing and able to provide written informed consent
    2) HCV genotype (GT) 1 (Historical result from prior Gilead study is acceptable)
    3) HCV RNA >LLOQ at Screening
    4) Participated in one of the following Gilead-sponsored studies:
    - Group 1
    o P7977-0221
    o P7977-0422 (PROTON)
    o P-7977-0724 (ATOMIC)
    o GS-US-334-0110 (NEUTRINO)
    o P2938-0721(QUANTUM)
    - Group 2
    o GS-US-337-0118 (LONESTAR)
    o GS-US-337-0133 (LONESTAR 3)
    o GS-US-337-0102 (ION-1)
    o GS-US-337-0108 (ION-3)
    o GS-US-337-0109 (ION-2)
    - Group 3
    o GS-US-334-0125
    - Subjects that participated in other Gilead-sponsored HCV treatment studies will require pre-approval by Gilead Medical Monitor or Study Director. Subjects must not have withdrawn consent or have been terminated early due to investigator
    discretion from the prior study.
    5) Liver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma (HCC) is required in patients with cirrhosis. Cirrhosis is defined as any of the following:
    o Prior diagnosis of cirrhosis
    o FibroTest score of > 0.75 AND an AST:platelet ratio index (APRI) of > 2 during Screening
    6) Screening ECG without clinically significant abnormalities
    7) Subjects must have the following laboratory parameters at screening
    - Group 1 & Group 2 only:
    o ALT </= 10 x the upper limit of normal (ULN)
    o AST </= 10 x ULN
    o Direct bilirubin </= 1.5 x ULN
    o Platelets >/= 50,000/µL
    o HbA1c </= 10%
    o Creatinine clearance (CLcr) >/= 60 mL /min, as calculated by the Cockcroft-Gault equation
    o Hemoglobin >/= 11 g/dL for female subjects; >/= 12 g/dL for male subjects.
    o Albumin >/= 3g/dL
    o INR </= 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.
    - Group 3:
    o Hemoglobin (Hb) > 10 g/dL
    o Platelets >/= 30,000/ mm3
    o Creatinine </= 2.5 times ULN, Creatinine clearance (CLcr) >/= 40 mL /min, as calculated by the Cockcroft-Gault equation
    o Sodium >125 mmol/L
    o Total bilirubin < 10 mg/dL
    Subjects who met laboratory eligibility criteria in their parent protocol, but do not fulfill all of the above requirements may be enrolled at the request of the Investigator and with the approval of the Medical Monitor or Study Director
    8) Females of childbearing potential (as defined in Appendix 4) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1 prior to randomization.
    9) Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix 4.
    10) Subject must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator.
    11) Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
    Los pacientes deben cumplir todos los criterios de inclusión siguientes a fin de ser aptos para participar en este estudio.
    1)Voluntad y capacidad para dar el consentimiento informado por escrito.
    2)VHC genotipo 1 (se acepta el resultado histórico de un estudio previo de Gilead).
    3)ARN del VHC > LIC en la selección.
    4)Participación en uno de los siguientes estudios promovidos por Gilead:
    - Grupo 1
    oP7977-0221
    oP7977-0422 (PROTON)
    oP-7977-0724 (ATOMIC)
    oGS-US-334-0110 (NEUTRINO)
    oP2938-0721(QUANTUM)
    -Grupo 2
    oGS-US-337-0118 (LONESTAR)
    oGS-US-337-0133 (LONESTAR 3)
    oGS-US-337-0102 (ION-1)
    oGS-US-337-0108 (ION-3)
    oGS-US-337-0109 (ION-2)
    -Grupo 3
    oGS-US-334-0125
    -Los pacientes que participaron en otros estudios de tratamiento del VHC promovidos por Gilead requerirán una autorización previa por parte del monitor médico o el director del estudio de Gilead.
    Los pacientes no deben haber retirado su consentimiento ni haber sido retirados anticipadamente del estudio anterior por el investigador.
    5)La exploración hepática por imagen en los 6 meses previos al inicio/día 1 es obligatoria en pacientes con cirrosis para descartar el carcinoma hepatocelular (CHC). La cirrosis se define como la presencia de alguno de los siguientes:
    oDiagnóstico previo de cirrosis.
    oPuntuación de FibroTest > 0,75 Y un índice de la relación AST:plaquetas (APRI) > 2 durante la selección.
    6)ECG en la selección sin anomalías clínicamente significativas.
    7)Los pacientes deben presentar los siguientes parámetros analíticos en la selección:
    -Grupos 1 y 2 solamente:
    oALT </= 10 x el límite superior de la normalidad (LSN)
    oAST </= 10 x LSN
    oBilirrubina directa </= 1,5 x LSN
    oPlaquetas </= 50.000/µl
    oHbA1c </= 10 %
    oAclaramiento de creatinina (Acr) >/= 60 ml/min, calculado mediante la fórmula de Cockcroft-Gault
    oHemoglobina >/= 11 g/dl en mujeres; >/= 12 g/dl en varones.
    oAlbúmina >/= 3 g/dl.
    oINR </= 1,5 x LSN, a menos que el paciente tenga hemofilia diagnosticada o esté estable en un tratamiento anticoagulante que afecta al INR.
    -Grupo 3:
    oHemoglobina (Hb) > 10 g/dl
    oPlaquetas >/= 30.000/mm3
    oCreatinina </= 2,5 x LSN, aclaramiento de creatinina (Acr) >/= 40 ml/min, calculado mediante la fórmula de Cockcroft-Gault.
    oSodio > 125 mmol/l
    oBilirrubina total < 10 mg/dl
    Los pacientes que cumplieran los criterios analíticos de idoneidad en el protocolo original, pero que no cumplan todos los requisitos anteriores podrán ser inscritos a petición del investigador, y con la aprobación del monitor médico o el director del estudio.
    8)Las mujeres en edad fértil (según la definición del Anexo 4) deben dar negativo en una prueba de embarazo en suero en la selección, y negativo en una prueba de embarazo en orina el día 1 antes de la aleatorización.
    9)Los pacientes fértiles de sexo masculino y femenino que mantengan relaciones sexuales deben aceptar el uso del método o los métodos anticonceptivos especificados en el protocolo, tal y como se describe en el Anexo 4.
    10)Los pacientes deben tener un buen estado de salud general, a excepción de la infección crónica por VHC, según la determinación del investigador.
    11)Los pacientes deben poder cumplir las instrucciones de administración del fármaco del estudio y ser capaces de completar el calendario de evaluaciones del estudio.
    E.4Principal exclusion criteria
    Subjects who meet any of the following exclusion criteria are not be enrolled in this study.
    1) Current or prior history of any of the following:
    a) Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol.
    b) Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
    2) Pregnant or nursing female or male with pregnant female partner.
    3) Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
    4) In the judgment of the investigator any clinically-relevant drug or alcohol abuse within 12 months of screening that may interfere with subject treatment, assessment or compliance with the protocol.
    5) Contraindications to RBV therapy, including significant history of clinically significant hemoglobinopathy (e.g., sickle cell disease, thalassemia).
    6) Use of any prohibited concomitant medications as described in the Protocol Section 5.4
    7) Known hypersensitivity to RBV, sofosbuvir, ledipasvir, the metabolites or formulation excipients.
    8) On-treatment virologic failure in prior Gilead-sponsored HCV treatment studies

    Group 1 and Group 2 Additional Exclusion Criteria
    9) Subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) [Groups 1& 2 only]
    10) Current or prior history of Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage) [Groups 1& 2 only].

    Group 3 Additional Exclusion Criteria
    11) Untreated, active variceal bleeding within 6 months of screening [Group 3 only]
    12) Patients with a Child-Pugh-Turcotte score > 12 [Group 3 only]
    13) History of organ transplant. Patients with prior liver or kidney transplant may be eligible with Medical Monitor approval. [Group 3 only]
    14) Any current signs or symptoms of severe hepatic encephalopathy, that in the opinion of the Investigator may affect the ability of the subject to provide initial and continuing informed consent to participate. [Group 3 only]
    15) History of hepatorenal, or hepatopulmonary syndrome. [Group 3 only]
    16) Active spontaneous bacterial peritonitis at screening. [Group 3 only]
    Los pacientes que cumplan cualquiera de los criterios de exclusión siguientes no pueden inscribirse en este estudio.
    1)Alguna de las siguientes enfermedades, en los antecedentes médicos o en curso:
    a)Enfermedad clínicamente significativa (aparte de la infección por VHC) o cualquier otro trastorno médico importante que pueda interferir en el tratamiento y la evaluación del paciente, o en el cumplimiento del protocolo.
    b)Trastorno gastrointestinal o afección posoperatoria que podría interferir en la absorción del fármaco del estudio.
    2)Mujer embarazada o lactante o varón con pareja embarazada.
    3)Infección por el virus de la hepatitis B (VHB) o el virus de la inmunodeficiencia humana (VIH).
    4)A criterio del investigador, cualquier abuso de alcohol o drogas clínicamente relevante en los 12 meses previos a la selección que pudiera interferir en el tratamiento y la evaluación del paciente, o en el cumplimiento del protocolo.
    5)Contraindicaciones para el tratamiento con RBV, incluidos antecedentes de hemoglobinopatía clínicamente significativa (p. ej., drepanocitosis, talasemia).
    6)Uso de algún medicamento concomitante prohibido según lo descrito en la Sección 5.4 del protocolo.
    7)Hipersensibilidad conocida a RBV, sofosbuvir, ledipasvir, los metabolitos o los excipientes de la formulación.
    8)Fracaso virológico durante el tratamiento en estudios anteriores en VHC promovidos por Gilead.

    Criterios de exclusión adicionales para los grupos 1 y 2
    9)Pacientes que estén siendo evaluados para detectar una enfermedad potencialmente significativa desde un punto de vista clínico (aparte de la infección por VHC) [grupos 1 y 2 solamente].
    10)Antecedentes o presencia de descompensación hepática clínica (esto es, ascitis, encefalopatía o hemorragia varicosa) [grupos 1 y 2 solamente].

    Criterios de exclusión adicionales para el grupo 3
    11)Hemorragia varicosa activa no tratada en los 6 meses anteriores a la selección [grupo 3 solamente].
    12)Pacientes con una puntuación Child-Pugh-Turcotte > 12 [grupo 3 solamente].
    13)Antecedentes de trasplante de órgano. Los pacientes con transplante previo hepático o renal podrían ser aptos, con la aprobación del monitor médico [grupo 3 solamente].
    14)Cualquier signo o síntoma en curso de encefalopatía hepática grave que, en opinión del investigador, pueda afectar a la capacidad del paciente para dar el consentimiento informado inicial para participar y continuar haciéndolo [grupo 3 solamente].
    15)Antecedentes de síndrome hepatopulmonar o hepatorrenal [grupo 3 solamente].
    16)Peritonitis bacteriana espontánea y activa en la selección [grupo 3 solamente].
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is SVR12 (HCV RNA <LLOQ 12 weeks after discontinuation of therapy) in the Full Analysis Set (FAS) population.
    El criterio principal de valoración de la eficacia es la RVS12 (ARN del VHC < LIC 12 semanas después de la interrupción del tratamiento) en la población del conjunto de análisis completo (FAS).
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 weeks after discontinuation of therapy
    12 semanas después de la interrupción del tratamiento
    E.5.2Secondary end point(s)
    The proportion of subjects with: HCV RNA < LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)

    The proportion of subjects with HCV RNA < LLOQ on treatment

    HCV RNA change from Baseline/Day 1

    The proportion of subjects with virologic failure
    La proporción de pacientes con: ARN del VHC < LIC a las 4 y 24 semanas tras la interrupción del tratamiento (RVS4 y RVS24).

    La proporción de pacientes con ARN del VHC < LIC durante el tratamiento.

    Cambio en el ARN del VHC desde el inicio/día 1.

    La proporción de pacientes con fracaso virológico.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Secondary endpoints will be assessed at On-Treatment visits at the end of Weeks 1, 4, 8, 12 and Post-Treatment visit Weeks 4, 12 (if applicable), and 24 (if applicable).

    For subjects in Groups 2 and 3, additional On-Treatment visits will occur at the end of
    Weeks 16, 20, and 24.
    Los criterios secundarios se examinarán en las visitas durante el tratamiento al final de las semanas 1, 4, 8 y 12, y visitas postratamiento en las semanas 4, 12 (si corresponde) y 24 (si corresponde).

    Los pacientes de los grupos 2 y 3 tendrán visitas adicionales durante el tratamiento al final de las semanas 16, 20 y 24.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA4
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    New Zealand
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Subject Last Visit
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 95
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 15
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 12
    F.4.2.2In the whole clinical trial 110
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who do not achieve SVR24 will be eligible for the Sequence Registry Study (Protocol GS-US-248-0123).

    Subjects who achieve SVR24 will be eligible for the SVR Registry Study (Protocol GS-US-248-0122).

    Cirrhotic subjects who achieve SVR24 will be eligible for the Cirrhosis SVR Registry Study which will be to evaluate durability of SVR and the progression or regression of liver disease for up to 5 years post-treatment (Protocol GS-US-337-1431).
    Los pacientes que no alcancen la RVS24 serán elegibles para el estudio de registro de secuencia (GS-US-248 0123)
    Los pacientes que alcancen la RVS24 serán elegibles para el estudio de registro de RVS (GS-US-248-0122)
    Los pacientes con cirrosis que alcancen una RVS24 serán elegibles para el estudio de registro de RVS y cirrosis, que evaluará la durabilidad de la RVS y la progresión o regresión de la hepatopatía durante un máximo de 5 años postratamiento (GS-US-337-1431)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-10-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-09-19
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-11-12
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:51:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA